Advertisement

Journal of Cell Communication and Signaling

, Volume 12, Issue 1, pp 245–252 | Cite as

Metabolic regulation of the CCN family genes by glycolysis in chondrocytes

  • Sho Akashi
  • Takashi Nishida
  • Abdellatif El-Seoudi
  • Masaharu TakigawaEmail author
  • Seiji Iida
  • Satoshi KubotaEmail author
Research Article

Abstract

The CCN family consists of 6 genes in the mammalian genome and produces multifunctional proteins involved in a variety of biological processes. Recent reports indicate the profound roles of CCN2 in energy metabolism in chondrocytes, and Ccn2 deficiency is known to alter the expression of 2 other family members including Ccn3. However, almost nothing is known concerning the regulation of the CCN family genes by energy metabolism. In order to gain insight into this critical issue, we initially and comprehensively evaluated the effect of inhibition of glycolysis on the expression of all of the CCN family genes in chondrocytic cells. Upon the inhibition of a glycolytic enzyme, repression of CCN2 expression was observed, whereas CCN3 expression was conversely induced. Similar repression of CCN2 was conferred by the inhibition of aerobic ATP production, which, however, did not induce CCN3 expression. In contrast, glucose starvation significantly enhanced the expression of CCN3 in those cells. The results of a reporter gene assay using a molecular construct containing a CCN3 proximal promoter revealed a dose-dependent induction of the CCN3 promoter activity by the glycolytic inhibitor in chondrocytic cells. These results unveiled a critical role of glycolytic activity in the regulation of CCN2 and CCN3, which activity mediated the mutual regulation of these 2 major CCN family members in chondrocytes.

Keywords

CCN2 CCN3 Glycolysis Metabolism Cartilage 

Notes

Acknowledgments

The authors thank Drs. Takako Hattori, Kazumi Kawata, Eriko Aoyama for their helpful support in experiments, as well as Ms. Yoshiko Miyake for her secretarial assistance. This study was supported by grants from the program Grants-in-aid for Scientific Research (B) [JP15H0514 to M.T.], and for Challenging Research (Exploratory) [JP17K19757 to M.T. and JP17K19756 to S.K.] from the Japan Society for the Promotion of Science.

References

  1. Abd El Kader T, Kubota S, Janune D, Nishida T, Hattori T, Aoyama E, Perbal B, Kuboki T, Takigawa M (2013) Anti-fibrotic effect of CCN3 accompanied by altered gene expression profile of the CCN family. J Cell Commun Signal 7:11–18CrossRefPubMedGoogle Scholar
  2. Abd El Kader T, Kubota S, Nishida T, Hattori T, Aoyama E, Janune D, Hara ES, Ono M, Tabata Y, Kuboki T, Takigawa M (2014) The regenerative effects of CCN2 independent modules on chondrocytes in vitro and osteoarthritis models in vivo. Bone 59:180–188CrossRefPubMedGoogle Scholar
  3. Chang CH, Curtis JD, Maggi LB Jr, Faubert B, Villarino AV, O'Sullivan D, Huang SC, van der Windt GJ, Blagih J, Qiu J, Weber JD, Pearce EJ, Jones RG, Pearce EL. (2013) Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153:1239–1251Google Scholar
  4. El-Seoudi A, Abd El Kader T, Nishida T, Eguchi T, Aoyama E, Takigawa M, Kubota S (2017) Catabolic effects of FGF-1 on chondrocytes and its possible role in osteoarthritis. J Cell Commun Signal.  https://doi.org/10.1007/s12079-017-0384-8
  5. Escoté X, Gómez-Zorita S, López-Yoldi M, Milton-Laskibar I, Fernández-Quintela A, Martínez JA, Moreno-Aliaga MJ, Portillo MP (2017) Role of omentin, vaspin, cardiotrophin-1, TWEAK and NOV/CCN3 in obesity and diabetes development. Int J Mol Sci 18.  https://doi.org/10.3390/ijms18081770
  6. Hao W, Chang CP, Tsao CC, Xu J (2010) Oligomycin-induced bioenergetic adaptation in cancer cells with heterogeneous bioenergetic organization. J Biol Chem 285:12647–12654CrossRefPubMedPubMedCentralGoogle Scholar
  7. Hoshijima M, Hattori T, Aoyama E, Nishida T, Yamashiro T, Takigawa M (2012) Roles of heterotypic CCN2/CTGF-CCN3/NOV and homotypic CCN2-CCN2 interactions in expression of the differentiated phenotype of chondrocytes. FEBS J 279:3584–3597CrossRefPubMedGoogle Scholar
  8. Itoh S, Hattori T, Tomita N, Aoyama E, Yutani Y, Yamashiro T, Takigawa M (2013) CCN family member 2/connective tissue growth factor (CCN2/CTGF) has anti-aging effects that protect articular cartilage from age-related degenerative changes. PLoS One 8:e71156CrossRefPubMedPubMedCentralGoogle Scholar
  9. Ivkovic S, Yoon BS, Popoff SN, Safadi FF, Libuda DE, Stephenson RC, Daluiski A, Lyons KM (2003) Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 130:2779–2791CrossRefPubMedPubMedCentralGoogle Scholar
  10. Janune D, Kubota S, Lazar N, Perbal B, Iida S, Takigawa M (2011) CCN3-mediated promotion of sulfated proteoglycan synthesis in rat chondrocytes from developing joint heads. J Cell Commun Signal 5:167–171CrossRefPubMedPubMedCentralGoogle Scholar
  11. Janune D, Abd El Kader T, Aoyama E, Nishida T, Tabata Y, Kubota S, Takigawa M (2017) Novel role of CCN3 that maintains the differentiated phenotype of articular cartilage. J Bone Miner Metab.  https://doi.org/10.1007/s00774-016-0793-4
  12. Jun JI, Lau LF (2011) Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 10:9459–9463CrossRefGoogle Scholar
  13. Kawaki H, Kubota S, Suzuki A, Lazar N, Yamada T, Matsumura T, Ohgawara T, Maeda T, Perbal B, Lyons KM, Takigawa M (2008) Cooperative regulation of chondrocyte differentiation by CCN2 and CCN3 shown by a comprehensive analysis of the CCN family proteins in cartilage. J Bone Miner Res 23:1751–1764CrossRefPubMedGoogle Scholar
  14. Kubota S, Takigawa M (2011) The role of CCN2 in cartilage and bone development. J Cell Commun Signal 5:209–217CrossRefPubMedPubMedCentralGoogle Scholar
  15. Kubota S, Takigawa M (2013) The CCN family acting throughout the body: recent research developments. Biomol Concepts 4:477–494CrossRefPubMedGoogle Scholar
  16. Kubota S, Takigawa M (2015) Cellular and molecular actions of CCN2/CTGF and its role under physiological and pathological conditions. Clin Sci (Lond) 128:181–196CrossRefGoogle Scholar
  17. Kubota S, Hattori T, Nakanishi T, Takigawa M (1999) Involvement of cis-acting repressive element(s) in the 3′-untranslated region of human connective tissue growth factor gene. FEBS Lett 450:84–88CrossRefPubMedGoogle Scholar
  18. Leask A, Abraham DJ (2006) All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119:4803–4810CrossRefPubMedGoogle Scholar
  19. Maeda-Uematsu A, Kubota S, Kawaki H, Kawata K, Miyake Y, Hattori T, Nishida T, Moritani N, Lyons KM, Iida S, Takigawa M (2014) CCN2 as a novel molecule supporting energy metabolism of chondrocytes. J Cell Biochem 115:854–865CrossRefPubMedPubMedCentralGoogle Scholar
  20. Nakanishi T, Nishida T, Shimo T, Kobayashi K, Kubo T, Tamatani T, Tezuka K, Takigawa M (2000) Effects of CTGF/Hcs24, a product of a hypertrophic chondrocyte-specific gene, on the proliferation and differentiation of chondrocytes in culture. Endocrinology 141:264–273CrossRefPubMedGoogle Scholar
  21. Nishida T, Kubota S, Nakanishi T, Kuboki T, Yosimichi G, Kondo S, Takigawa M (2002) CTGF/Hcs24, a hypertrophic chondrocyte-specific gene product, stimulates proliferation and differentiation, but not hypertrophy, of cultured articular chondrocytes. J Cell Physiol 192:55–63CrossRefPubMedGoogle Scholar
  22. Nishida T, Kubota S, Kojima S, Kuboki T, Nakao K, Kushibiki T, Tabata Y, Takigawa M (2004) Regeneration of defects in articular cartilage in rat knee joints by CCN2 (connective tissue growth factors). J Bone Miner Res 19:1308–1319CrossRefPubMedGoogle Scholar
  23. Perbal B, Takigawa M (2005) CCN protein -a new family of cell growth and differentiation regulators. Imperial College Press, London, pp 1–311CrossRefGoogle Scholar
  24. Rachfal AW, Brigstock DR (2005) Structural and functional properties of CCN proteins. Vitam Horm 70:69–103CrossRefPubMedGoogle Scholar
  25. Riser BL, Najmabadi F, Perbal B, Peterson DR, Rambow JA, Riser ML, Sukowski E, Yeger H, Riser SC (2009) CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am J Pathol 174:1725–1734CrossRefPubMedPubMedCentralGoogle Scholar
  26. Takigawa M, Tajima K, Pan HO, Enomoto M, Kinoshita A, Suzuki F, Takano Y, Mori Y (1989) Establishment of a clonal human chondrosarcoma cell line with cartilage phenotypes. Cancer Res 49:3996–4002PubMedGoogle Scholar

Copyright information

© The International CCN Society 2017

Authors and Affiliations

  1. 1.Department of Biochemistry and Molecular DentistryOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan
  2. 2.Department of Oral and Maxillofacial Reconstructive SurgeryOkayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayamaJapan
  3. 3.Advanced Research Center for Oral and Craniofacial SciencesOkayama University Dental SchoolOkayamaJapan

Personalised recommendations